Close Menu

NEW YORK – Invitae and ArcherDx announced Monday morning that the two genetic testing companies have agreed to merge in order to expand their footprint in the cancer genetics and precision oncology space.

Invitae said that it would acquire privately held ArcherDx through a combination of 30 million shares of its common stock and $325 million in cash, plus an additional 27 million shares of common stock if certain milestones are achieved. The overall transaction is valued at approximately $1.4 billion.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports that US states and territories are seeking more funding for the distribution of SARS-CoV-2 vaccines.

The strain now accounts for about 80 percent of cases in Wales and Scotland, and about half of cases in England, the Guardian reports.

A new study suggests that using CRISPR to edit human embryonic DNA can lead to the loss of whole chromosomes, as the Associated Press reports.

In Science this week: ancient dog genomes highlight long ties with humans, genomic analysis of 40,000-year-old early East Asian individual, and more.